{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+2+Hypertension",
    "query": {
      "condition": "Stage 2 Hypertension"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 186,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+2+Hypertension&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T13:20:42.217Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01873885",
      "title": "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo Single IV (Intravenous) Infusion",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Single IV Infusion Vasomera (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873885"
    },
    {
      "nct_id": "NCT05451329",
      "title": "A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "VVN539 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VivaVision Biotech, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2022-07-12",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05451329"
    },
    {
      "nct_id": "NCT07553442",
      "title": "A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "ALN-AGT01 RVR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Zilebesiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 93,
      "start_date": "2026-04-27",
      "completion_date": "2028-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 3,
      "location_summary": "Lake Forest, California • Tampa, Florida • Savannah, Georgia",
      "locations": [
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07553442"
    },
    {
      "nct_id": "NCT01508026",
      "title": "Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage 1 Hypertension",
        "Stage 2 Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol and Valsartan 1",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol and Valsartan 2",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol and Valsartan 3",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol 1",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol 2",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 1",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4161,
      "start_date": "2012-01",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2014-04-25",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 413,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01508026"
    },
    {
      "nct_id": "NCT00376181",
      "title": "Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Pioglitazone and Azilsartan",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2006-06",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2010-06-22",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 59,
      "location_summary": "Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tallassee",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376181"
    },
    {
      "nct_id": "NCT05001945",
      "title": "Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension, Renal"
      ],
      "interventions": [
        {
          "name": "MLS-101 (Part I)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Part I)",
          "type": "OTHER"
        },
        {
          "name": "Placebo (Part II)",
          "type": "OTHER"
        },
        {
          "name": "MLS-101 (Part II)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mineralys Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2021-07-01",
      "completion_date": "2022-10-07",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 44,
      "location_summary": "Lincoln, California • Torrance, California • Tustin, California + 38 more",
      "locations": [
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001945"
    },
    {
      "nct_id": "NCT02603809",
      "title": "Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Aprocitentan 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1659,
      "start_date": "2015-12-14",
      "completion_date": "2017-04-07",
      "has_results": true,
      "last_update_posted_date": "2022-11-23",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 74,
      "location_summary": "Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more",
      "locations": [
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603809"
    },
    {
      "nct_id": "NCT07064473",
      "title": "EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hypertension",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Vicadrostat",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Vicadrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11800,
      "start_date": "2025-07-22",
      "completion_date": "2029-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 216,
      "location_summary": "Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 177 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064473"
    },
    {
      "nct_id": "NCT06152861",
      "title": "Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travoprost Ophthalmic Topical Cream low-dose",
          "type": "DRUG"
        },
        {
          "name": "Travoprost Ophthalmic Topical Cream mid-dose",
          "type": "DRUG"
        },
        {
          "name": "Travoprost Ophthalmic Topical Cream high-dose",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate ophthalmic solution, 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Travoprost Ophthalmic Solution, 0.004%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2023-11-15",
      "completion_date": "2024-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06152861"
    },
    {
      "nct_id": "NCT04499248",
      "title": "AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AGN-193408 SR",
          "type": "DRUG"
        },
        {
          "name": "Lumigan",
          "type": "OTHER"
        },
        {
          "name": "Sham Administration",
          "type": "OTHER"
        },
        {
          "name": "Lumigan Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-11-16",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-07T13:20:42.217Z",
      "location_count": 42,
      "location_summary": "Sun City, Arizona • Glendale, California • Inglewood, California + 38 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04499248"
    }
  ]
}